Summary of Study ST003147

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001941. The data can be accessed directly via it's Project DOI: 10.21228/M8TM76 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003147
Study TitleBT-474 cells fed with [13C2] acetate and treated with 1 uM Fasnall or 1 uM GSK2194069 for 24 h
Study TypeIntracellular metabolomics, [13C2] acetate
Study SummaryBT-474 breast cancer cells were fed with [13C2] acetate and treated with 1 uM Fasnall or 1 uM GSK2194069 for 24 h. Cells were grown in RPMI-1640 with 10% dialyzed FBS.
Institute
Wistar Institute
DepartmentMolecular and Cellular Oncogenesis Program, Ellen and Ronald Caplan Cancer Center
LaboratorySchug's Lab
Last NameMukha
First NameDzmitry
Address3601 Spruce St, Philadelphia, PA 19104, USA
Emaildmukha@wistar.org
Phone2154956903
Submit Date2024-03-09
Num Groups3
Total Subjects9
PublicationsSubmission Pending
Raw Data AvailableYes
Raw Data File Type(s)mzXML, raw(Thermo)
Analysis Type DetailLC-MS
Release Date2024-04-02
Release Version1
Dzmitry Mukha Dzmitry Mukha
https://dx.doi.org/10.21228/M8TM76
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Treatment:

Treatment ID:TR003273
Treatment Summary:Cells were grown in RPMI-1640 supplemented with 200 uM [13C2] acetate and treated with 1 uM Fasnall or 1 uM GSK2194069.
Treatment Compound:Fasnall, GSK2194069
Treatment Dose:0 - 1 uM
Treatment Doseduration:24 h
Treatment Vehicle:DMSO
Cell Growth Container:6-well plates
Cell Media:RPMI-1640
Cell Envir Cond:37C, 5% CO2
Cell Pct Confluence:~70%
  logo